Summary. Background: Circulating tumor cell (CTC) count is a major prognostic factor in metastatic breast cancer (MBC) and has been reported to be associated with thrombosis in short-term studies on MBC patients. Objective: To assess whether CTC detection (CellSearch Ò ) before first-line chemotherapy impacts the risk of thrombosis throughout the course of MBC. Patients/Methods: Among patients included before first-line chemotherapy for MBC in the prospective IC2006-04 CTC detection study (NCT00898014), the electronic medical files of those patients treated at Institut Curie (Paris, France) were searched in silico and manually checked for incident venous or arterial thrombotic events (TE) in the course of MBC. Univariate and multivariate analyses were performed using Cox and Fine-Gray models, adjusted for age and Khorana score. Results/Conclusions: With a median follow-up of 64 months (25-81 months), among the 142 patients included, 34 (24%) experienced a TE (incidence rate, 8 TE/100 patient-years). The TE incidence rate was 13 TE/100 patient-years for the 80 patients with ≥ 1 CTC/7.5 mL of blood before initiating first-line chemotherapy, vs. only 4 TE/100 patient-years for the 62 CTC-negative patients. Fine-Gray multivariate analysis (with death as competing event) included age, Khorana score and baseline lactate dehydrogenase and CTC levels: detectable CTC was the only factor significantly associated with an increased risk of TE (sub-distribution hazard ratio [SHR] for patients with [1] [2] [3] [4] ] CTC = 3.1, 95% CI [1.1; 8.6], SHR for patients with ≥ 5 CTC = 1.4, 95% CI [0. 5; 4.6] ). This study shows that CTC detection before starting first-line chemotherapy is an independent risk factor for TE in MBC patients.
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Background
A cancer-related thrombotic event (TE) is a frequent and possibly life-threatening condition. Known risk factors for TEs are age, cancer histology, presence of metastases, use of chemotherapy, presence of central venous catheters, altered performance status (PS), anemia, thrombocytosis and high body mass index [1] . The Khorana score [2] , based on type of cancer, body mass index, platelet count, leukocyte count and hemoglobin level, has been validated as a predictor of the risk of a venous TE in cancer patients. In early breast cancer, a meta-analysis reported an overall low incidence of about 10 TE/1000 patient-years [3] , but the incidence of TEs in metastatic breast cancer (MBC) patients remains uncertain because of the different methods used to detect TEs and heterogeneous follow-up (11 to 176/1000 patients-years [3] ).
The underlying mechanisms of cancer-related TEs have been reviewed elsewhere [3, 4] . Among these various mechanisms, tissue factor activity has been correlated with tumor burden and detection of tumor cells in blood [5, 6] . These cells, known as circulating tumor cells (CTCs), have been repeatedly reported to be a major prognostic factor in MBC patients, for both progression-free and overall survival (OS) [7] [8] [9] . Furthermore, preclinical data suggest that CTCs can contribute to the formation of circulating tumor microthrombi, which, in turn, can increase the incidence of TEs in cancer patients [10] . In a short follow-up study, Mego et al. reported that CTC count may be associated with TEs in MBC patients [11] . However, the evidence supporting the correlation between CTC detection and occurrence of TEs currently remains unclear, as reviewed by Castle et al. [12] and more recently by Mitrugno et al. [13] .
Objective
This post-hoc study investigated whether CTC count before starting first-line chemotherapy is associated with a risk of TE, throughout the course of the disease in a population of MBC patients included in a prospective study (IC2006-04).
Methods

Study design: medical file inspection
The IC2006-04 study was a prospective study conducted in five French cancer centers, designed to confirm that CTC count at baseline and 3-5 weeks after a first cycle of first-line chemotherapy was a dynamic prognostic factor in MBC patients (NCT00898014). CTC count was determined by experienced technicians using the standardized CellSearch Ò system (Janssen Diagnostics, Raritan, NJ, USA). Patients were followed-up according to routine practice. All patients receiving first-line chemotherapy for MBC with a life expectancy longer than 3 months were eligible. This study, which included 267 patients, after obtaining their written informed consent (including 148 patients at Institut Curie, Paris, France), treated between June 2007 and September 2009, confirmed the association between elevated CTC count and poorer OS [7] . This post-hoc analysis of the IC2006-04 study included all 142 patients enrolled at Institut Curie (Paris, France) for whom a baseline CTC count was available; patients enrolled in the other four centers or with missing baseline CTC count were not included (flow diagram, Figure S1 ). Patient follow-up started at inclusion in the IC2006-04 study, and ended at date of death or date of last visit. In the previous report [7] , survival analyses were performed on survival data collected up until 20 October 2010, whereas, in the present study, survival analyses were performed on survival data collected up until 28 April 2014 (date of last recorded visit Cyfra21.1. LDH and liver enzymes were expressed as multiples of the upper limit of normal. Khorana score was calculated using baseline patient characteristics [2] . Patient electronic medical files were searched for documented venous and arterial thrombosis occurring after inclusion and throughout the course of the disease until the patient's death or last visit. TEs were defined as any documented, symptomatic or incidental arterial (ischemic stroke, myocardial infarction and peripheral arterial thrombosis) or venous (deep vein thrombosis, pulmonary embolism, catheter-related thrombosis and visceral vein thrombosis) thrombosis occurring after study inclusion and throughout the course of MBC. As TEs were recorded retrospectively, their provoked or unprovoked nature could not be assessed. Superficial vein thrombosis was not considered to be TE. The investigation was based on two approaches: manual inspection and in silico search of electronic medical records. In silico search consisted of using keywords related to the occurrence and/or treatment of TE: 'thrombosis', 'thromb*', 'phlebitis', 'embolism', 'pulmonary embolism', 'venous Doppler', 'angioscan' and anticoagulants (using generic and brand names). In patients experiencing multiple TEs, only the first TE was taken into account. Deaths were recorded in the same way as TEs.
Statistical analyses
Categorical variables were compared by chi-squared test or Fisher's exact test, and continuous variables by Student's t-test. Median follow-up was estimated using the reverse Kaplan-Meier method. Patients who survived and who did not experience a TE were censored at the date of last visit. As death is a competing risk for TEs, assessment of TE risk based on survival analysis was performed according to methodological recommendations for competing risks frameworks, using cumulative incidence functions, models for cause-specific hazards ratio (CSHR) and sub-distribution hazards ratio (SHR) [14] . A Cox model [15] was used for regression on CSHRs, whereas a FineGray model was used for regression on SHRs [16] . All univariate analyses were performed with and without adjustment for the available known potential confounders for TE risk (age and Khorana score). Variables with a Pvalue ≤ 0.05 in adjusted univariate analyses were included in multivariate analyses using a Cox model or Fine-Gray model for assessment of TE risk. Potential confounders (age and Khorana score) were also included in multivariate analyses as forced-in variables. The most significant variable of CTC count in univariate analysis was used for multivariate analysis. Cumulative CSHs were estimated non-parametrically using the complement of the KaplanMeier product estimator (1-KM). The cumulative incidence of TEs was displayed by the Fine-Gray method for competing risks. The assumption of proportionality of CSHR and SHR was checked using Schoenfeld residuals. Univariate and multivariate analysis using a Cox model was also used to assess the risk of death.
Analyses were performed using R software (version 3.0.1; http://cran.r-project.org). Significance was defined as P ≤ 0.05.
Results and discussion
All 142 patients primarily enrolled in the IC2006-04 study at Institut Curie (Paris, France) for whom baseline CTC count was available were included in this post-hoc analysis ( Figure S1 ); 100 (70%) of these patients had died at the time of analysis. The updated median follow-up for the patients included was 64 months (range, 25-81 months). Population characteristics are summarized in Table 1 . Briefly, 90% of patients had invasive breast ductal carcinoma, 63% had hormone receptor-positive tumors, 8% had a PS ≥ 2, 35% had more than two metastatic sites and 57% had ≥ 1 CTC at baseline. CTC detection before starting first-line chemotherapy was associated with altered PS, elevated LDH levels, elevated Cyfra21.1 levels, and presence of bone metastases (Table 1) . Univariate and multivariate analyses of the association between baseline CTC count and OS are displayed in Table S1 . Baseline CTC ≥ 1 was associated with poorer OS (CSHR = 1.9; 95% confidence interval, [1.2; 2.8]).
Thirty-four patients (24%) experienced one or more TEs, corresponding to an overall incidence of 8.2 TE/100 patient-years (95% CI, [5.5; 11 .0]), none of which occurred in the 6 weeks following surgery. Among these TE, thrombotic events; CSHR, cause-specific hazard ratio, calculated with Cox model; SHR, sub-distribution hazard ratio, calculated with Fine-Gray model; 95% CI, 95% confidence interval; HR, hormone receptors; HER2, human epidermal growth factor receptor 2; LLN, lower limit of normal value; ULN, upper limit of normal value; LDH, lactate dehydrogenase; CTC, circulating tumor cell. *Non-adjusted CSHR and SHR. †CSHR and SHR adjusted on age and Khorana Score.
34 patients, 24 (71%) died thereafter. Only one of the 32 patients alive without a TE was lost to follow-up (no data available for > 6 months Table 2 ). Figure 1 displays the cumulative incidence of TEs and death according to baseline CTC count. Multivariate analyses confirmed that patients with CTC detected at baseline were at higher risk of a TE (Table 2) .
Finally, as the IC2006-04 study prospectively assessed early CTC changes during first-line chemotherapy, we investigated whether CTC detection at 3-5 weeks was Cumulative incidence of thrombotic events and death according to baseline CTC count. CSH, cause-specific hazard; SH, sub-distribution hazard; CTC, circulating tumor cells. Cause-specific hazards do not take into account competing events; sub-distribution hazard of thrombotic events takes into account death as a competing risk. associated with TEs. Among 108 patients with available CTC data, 32 patients had ≥ 1 CTC detected at 3 weeks (29%); no significant association with a higher risk of a TE was observed in these patients, taking death into account as a competitive event (Table 2) in univariate analysis. The association between persistent detectable CTC during therapy and a TE was not assessed in multivariate analysis because of its strong association with baseline positive CTC count and the limited size of our study. Larger studies are warranted to assess the effect of tumor response to treatment, reflected by CTC count change during therapy, on thrombosis, and to provide clinical validation of studies reporting the mechanisms linking thrombosis and cancer progression [17] . The molecular mechanisms of the impact of CTCs on hemostasis have been reviewed elsewhere [10, 13, 18, 19] . CTC has recently been reported to be a potential component of the metastatic process [20] .
To our knowledge, no large clinical studies with longterm follow-up have been reported, and scores estimating the risk of thrombosis in cancer patients are of limited value in MBC patients, who have an overall low incidence of thrombosis: the Khorana score, which was not associated with TE risk in our study, was developed in breast cancer patients as a reference to estimate the risk of TEs in various types of cancer [2] . We observed a TE incidence of 82/1000 person-years, consistent with previous reports in patients with metastatic diseases [2, 3] .
Our study assessed the long-term thrombotic risk throughout the course of MBC (from initiation of firstline chemotherapy to death or loss to follow-up), and complements the cohort previously reported by Mego et al. [11] . This report concerned a retrospective study on 290 MBC patients followed during one second-line or greater line of therapy for advanced MBC. In line with our results based on long-term follow-up, Mego et al. found that ≥1 CTC at baseline was an independent risk factor for TE (using a Cox model) and a non-significant trend was observed when using ≥ 5 CTCs.
Our study has several limitations. In addition to the limited number of patients, the TE rate may have been underestimated because of retrospective recording of TEs. It is likely that TEs occurring in terminally ill patients (e.g. in palliative care units) were not systematically investigated and reported in the medical records. The use of thromboprophylaxis could also not be retrospectively assessed in these patients. In addition, the CellSearch Ò CTC detection technique has a limited sensitivity to CTCs expressing low levels of EpCAM and CTCs that have undergone epithelial-mesenchymal transition [21] .
Whether decreased CTC count during therapy is significantly associated with decreased risk of a TE remains to be confirmed. However, our data support the idea that baseline CTC count, whenever available, should be taken into account when considering the need for primary thromboprophylaxis in MBC patients. 
